Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDK8_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDK8_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDK8_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDK8_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDK8_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDK8_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK8 | SNV | Missense_Mutation | | c.790N>A | p.Asp264Asn | p.D264N | P49336 | protein_coding | tolerated(0.13) | benign(0.073) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
CDK8 | insertion | Frame_Shift_Ins | novel | c.1052_1053insG | p.Ile351MetfsTer15 | p.I351Mfs*15 | P49336 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CDK8 | insertion | Frame_Shift_Ins | novel | c.1053_1054insTTTCCAGTTAAGAGGCATT | p.Pro352PhefsTer20 | p.P352Ffs*20 | P49336 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CDK8 | insertion | Frame_Shift_Ins | novel | c.983_984insATACAAAATTAGCTGGGCATGGT | p.Ala329TyrfsTer16 | p.A329Yfs*16 | P49336 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDK8 | SNV | Missense_Mutation | | c.968G>A | p.Arg323Gln | p.R323Q | P49336 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CDK8 | SNV | Missense_Mutation | | c.1378N>G | p.Gln460Glu | p.Q460E | P49336 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.953) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
CDK8 | SNV | Missense_Mutation | | c.1115N>G | p.Asn372Ser | p.N372S | P49336 | protein_coding | tolerated(0.81) | benign(0.001) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CDK8 | SNV | Missense_Mutation | novel | c.515N>A | p.Ala172Asp | p.A172D | P49336 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CDK8 | SNV | Missense_Mutation | | c.1280N>T | p.Pro427Leu | p.P427L | P49336 | protein_coding | tolerated_low_confidence(0.08) | benign(0.285) | TCGA-CM-6675-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | fluorouracil | PD |
CDK8 | SNV | Missense_Mutation | novel | c.471N>G | p.Ile157Met | p.I157M | P49336 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | | ILORASERTIB | ILORASERTIB | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | CHEMBL3544942 | RONICICLIB | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 178102513 | PONATINIB | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 363894179 | | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 310264726 | | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 363894181 | | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | | AST-487 | AST-487 | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 375973251 | | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | | Macrocycle derivative 14 | | |
1024 | CDK8 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, TUMOR SUPPRESSOR | inhibitor | 249565898 | | |